Medivir Posts Modest Revenue Gain as EBITDA Loss Narrows, Funds Raised to Advance Clinical Programs
Swedish drug developer Medivir reported a small rise in first-quarter revenue and a reduced EBITDA loss, while completing a SEK 45 million directed share issue to support ongoing and planned clinical trials. Cash balances increased during the quarter and the company outlined near-term study starts and a veterinary study timeline into 2026.